Adoptively transferred CMV-specific CD8⁺T_CM/Eexhibit superior protection from tumor challenge. (A) Schematic of the in vivo tumor challenge experiment. (B) Engraftment of pp65⁺ ffLuc⁺ LCL in animals treated with or without CMV-specific T_CM/E or T_EM/E was determined by Xenogen imaging; and mean (± SE) of total flux levels of luciferase activity are shown for each group (n = 5). *P < .05, animals treated with T_CM/E versus either untreated or T_EM/E-treated animals (analysis of variance). (C) Mean percentage (± SE) of human CD45⁺CD8⁺ cells in day 10 mouse PBL was determined by flow cytometry. *P < .05, T_CM/E versus T_EM/E engraftment (unpaired Student t test).